Literature DB >> 18923178

Angiotensin II blockade in Marfan's syndrome.

Anna A Ahimastos, Anthony M Dart, Bronwyn A Kingwell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18923178     DOI： 10.1056/NEJMc081528

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Total serum transforming growth factor-β1 is elevated in the entire spectrum of genetic aortic syndromes.

Authors:  Mathias Hillebrand; Nathalie Millot; Sara Sheikhzadeh; Meike Rybczynski; Sabine Gerth; Tilo Kölbel; Britta Keyser; Kerstin Kutsche; Peter N Robinson; Jürgen Berger; Thomas S Mir; Tanja Zeller; Stefan Blankenberg; Yskert von Kodolitsch; Britta Goldmann
Journal:  Clin Cardiol       Date:  2014-08-11       Impact factor: 2.882

2.  Novel pharmacological strategies to prevent aortic complications in Marfan syndrome.

Authors:  Peter Matt; Friedrich Eckstein
Journal:  J Geriatr Cardiol       Date:  2011-12       Impact factor: 3.327

3.  TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial.

Authors:  Dylan R Morris; Margaret A Cunningham; Anna A Ahimastos; Bronwyn A Kingwell; Elise Pappas; Michael Bourke; Christopher M Reid; Theo Stijnen; Ronald L Dalman; Oliver O Aalami; Jan H Lindeman; Paul E Norman; Philip J Walker; Robert Fitridge; Bernie Bourke; Anthony E Dear; Jenna Pinchbeck; Rene Jaeggi; Jonathan Golledge
Journal:  Trials       Date:  2015-06-17       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.